SEC Form 4 · accession 0001663758-26-000002
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marion McCourt
Officer — EVP Commercial
Period of report
Sep 2, 2026
Accepted (ET)
Sep 3, 2026 · 4:50 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 2, 2026 | S | 1,215 | $850.00 | D | 13,134 | D | |
| Common Stock | Sep 3, 2026 | S | 1,131 | $857.39 | D | 12,003 | D | |
| Common Stock | holding | — | — | — | 219 | I | By 401(k) Plan |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.